Phase 2Completed
Assessment of Acute Psychomotor Agitation Measures Associated With Schizophrenia and Bipolar Disorder
- Sponsor
- BioXcel Therapeutics Inc (Industry)
- Enrolment
- 33 enrolled
- Conditions
- Bipolar I Disorder; Bipolar II Disorder; Schizophrenia; Schizoaffective Disorder; Schizophreniform Disorders; Psychomotor Agitation
- Interventions
- BXCL501 Sublingual Film
- Ages
- adults, older adults
- Registry
- NCT07116694
Full record on ClinicalTrials.gov
From the registry
This open-label study will utilize treatment with BXCL501 in order to assess the suitability of patient-and lay informant-assessed outcome measures for evaluation of severity of psychomotor agitation episodes in patients with Bipolar Disorders, Schizophrenia, Schizoaffective, and Schizophreniform disorders and correlate them with clinician-assessed ratings.
Primary outcomes
- Informant and Clinician ratings comparison
- Informant training materials assessment
History
Last registry update
Primary completion
Registered
Started